GlassScriptPhysician profile
Jay T Rains
NPI 1043718331
$5,245.37
in general payments reported to CMS, 2019-2025
35 companies · $1,303 in 2025
The $1,303 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $571 · 2022: $1,107 · 2023: $1,041 · 2024: $1,225 · 2025: $1,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,371 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,370.51 |
| Education | $197.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $725.70 | 2021-2025 | |
| Janssen Biotech, INC. | $618.29 | 2022-2025 | Erleada, Rybrevant, Carvykti |
| Abbvie INC. | $411.44 | 2021-2025 | |
| Astellas Pharma US INC | $389.55 | 2021-2025 | Xtandi, Veozah |
| Teleflex LLC | $333.93 | 2022-2025 | Urolift, Barrigel |
| Pfizer INC. | $298.75 | 2021-2025 | |
| Myovant Sciences INC. | $275.63 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $246.29 | 2023-2025 | Orgovyx |
| Dendreon Pharmaceuticals LLC | $215.27 | 2023-2025 | Provenge |
| Progenics Pharmaceuticals, INC. | $181.22 | 2022-2024 | Pylarify |
| Ferring Pharmaceuticals INC. | $148.85 | 2024-2025 | Adstiladrin |
| Myriad Genetic Laboratories, INC. | $140.38 | 2021-2024 | Prolaris |
| Boston Scientific Corporation | $130.14 | 2021-2025 | Ams 700, General - Erectile Dysfunction, Axonics |
| Antares Pharma, INC. | $119.00 | 2021-2025 | Xyosted |
| Tolmar, INC. | $116.81 | 2023-2025 | Jatenzo, Eligard |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $115.14 | 2021-2022 | |
| Blue Earth Diagnostics | $109.70 | 2021-2024 | |
| Endo USA, INC. | $88.06 | 2025 | Xiaflex |
| Endo Pharmaceuticals INC. | $86.71 | 2022-2024 | Xiaflex |
| Halozyme INC | $57.22 | 2023 | |
| Verity Pharmaceuticals INC. | $56.88 | 2024-2025 | Trelstar |
| Kowa Pharmaceuticals America, INC. | $54.01 | 2022-2023 | Seglentis |
| Janssen Pharmaceuticals, INC | $44.97 | 2022 | |
| Sun Pharmaceutical Industries INC. | $35.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $35.05 | 2021-2022 | |
| Olympus America INC. | $29.98 | 2024-2025 | Itind System |
| Tempus Ai, INC | $27.49 | 2025 | Xt Cdx |
| Accord Healthcare, INC. | $22.05 | 2024 | |
| Palette Life Sciences, INC. | $21.68 | 2022 | |
| Immunitybio, INC. | $21.25 | 2025 | |
| Calyxo, INC. | $20.39 | 2024 | Cvac Aspiration System |
| Abc Home Medical Supply, INC. | $20.28 | 2025 | |
| Rochester Medical Corporation | $19.03 | 2021 | |
| Ambu INC. | $14.40 | 2021 | |
| Hollister Incorporated | $13.84 | 2023 | Vapro Pocket |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Rains listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.